Market Cap (In USD)
13.17 Million
Revenue (In USD)
-
Net Income (In USD)
-23.53 Million
Avg. Volume
3.94 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.8-152.4
- PE
- -
- EPS
- -
- Beta Value
- -0.907
- ISIN
- US17248W2044
- CUSIP
- 17248W105
- CIK
- 1862150
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Shane J. Schaffer Pharm.D.
- Employee Count
- -
- Website
- https://www.cingulate.com
- Ipo Date
- 2021-12-08
- Details
- Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
More Stocks
-
SUH
-
9562
-
DHB
-
MTG-A
-
CXDOCrexendo, Inc.
CXDO
-
MRM
-
KRG
-
300199